Ligand Pharmaceuticals (LGND) Other Operating Expenses (2010 - 2026)

Ligand Pharmaceuticals has disclosed Other Operating Expenses across 16 years of filings, most recently posting $11.4 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $11.4 million, down 10.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.2 million (up 3.66% YoY), and the FY2023 annual result was $2.1 million, changed N/A from the prior year.
• Other Operating Expenses came in at $11.4 million for Q1 2026 at Ligand Pharmaceuticals, down from $17.3 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $37.7 million in Q2 2024 to a low of $2.1 million in Q3 2023.
• The 5-year median for Other Operating Expenses is $12.3 million (2023), against an average of $13.8 million.
• Across the five-year window, Other Operating Expenses jumped 268.87% in 2024 and sank 66.96% in 2025, its largest moves.
• Ligand Pharmaceuticals' Other Operating Expenses stood at $13.3 million in 2022, then sank by 84.03% to $2.1 million in 2023, then soared by 1675.29% to $37.7 million in 2024, then tumbled by 54.1% to $17.3 million in 2025, then sank by 34.22% to $11.4 million in 2026.
• The last three Other Operating Expenses figures came in at $11.4 million (Q1 2026), $17.3 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.